Repurposing Drugs for Cancer Radiotherapy Early Successes and Emerging OpportunitiesKhan, Mohammad K., MD, PhD; Nasti, Tahseen H., PhD; Buchwald, Zachary S., MD, PhD; Weichselbaum, Ralph R., MD; Kron, Stephen J., MD, PhDThe Cancer Journal: March/April 2019 - Volume 25 - Issue 2 - p 106–115 doi: 10.1097/PPO.0000000000000369 Review Articles Buy SDC Abstract Author InformationAuthors Article MetricsMetrics It has long been recognized that combining radiotherapy with cytotoxic drugs such as cisplatin can improve efficacy. However, while concurrent chemoradiotherapy improves patient outcomes, it comes at costs of increased toxicity. A tremendous opportunity remains to investigate drug combinations in the clinical setting that might increase the benefits of radiation without additional toxicity. This chapter highlights opportunities to apply repurposing of drugs along with a mechanistic understanding of radiation effects on cancer and normal tissue to discover new therapy-modifying drugs and help rapidly translate them to the clinic. We survey candidate radiosensitizers that alter DNA repair, decrease hypoxia, block tumor survival signaling, modify tumor metabolism, block growth factor signaling, slow tumor invasiveness, impair angiogenesis, or stimulate antitumor immunity. Promising agents include widely used drugs such as aspirin, metformin, and statins, offering the potential to improve outcomes, decrease radiation doses, and lower costs. Many other candidate drugs are also discussed. From the Winship Cancer Institute, Emory University, Atlanta, GA; and Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Mohammad K. Khan, MD, PhD, 1365 Clifton Rd NE, Office A1312, Atlanta, GA 30345. E-mail: email@example.com. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.